Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Prepaid Assets: 2019-2025

Historic Prepaid Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $7.3 million.

  • 4D Molecular Therapeutics' Prepaid Assets fell 17.50% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 17.50%. This contributed to the annual value of $10.1 million for FY2024, which is 20.33% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Prepaid Assets stood at $7.3 million for Q3 2025, which was down 27.31% from $10.1 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Prepaid Assets high stood at $11.1 million for Q1 2025, and its period low was $3.3 million during Q3 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Prepaid Assets value was $8.9 million (recorded in 2024), while the average stood at $9.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Prepaid Assets spiked by 90.28% in 2021 and then fell by 17.73% in 2022.
  • 4D Molecular Therapeutics' Prepaid Assets (Quarterly) stood at $8.5 million in 2021, then decreased by 17.73% to $7.0 million in 2022, then grew by 20.11% to $8.4 million in 2023, then climbed by 20.33% to $10.1 million in 2024, then fell by 17.50% to $7.3 million in 2025.
  • Its Prepaid Assets stands at $7.3 million for Q3 2025, versus $10.1 million for Q2 2025 and $11.1 million for Q1 2025.